Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva: A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features

G. K.P. Bittermann; D. C. Koper; L. A.A. Vaassen; M. F.C.M. van den Hout; P. A.W.H. Kessler

doi:10.1016/j.oor.2023.100111

Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva: A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features

G. K.P. Bittermann^*, D. C. Koper, L. A.A. Vaassen, M. F.C.M. van den Hout, P. A.W.H. Kessler

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Oral ulcerations of the gingiva or mucosa require differential diagnosis. One of these diagnoses may be Epstein-Barr virus (EBV)-positive mucocutaneous ulcer. Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a rare diagnosis and was first described in 2010. It is described as an Epstein-Barr virus (EBV)-mediated B-cell proliferation and occurs in patients with immunosuppression, e.g., therapy with azathioprine, methotrexate, or cyclosporine, but also in patients with age-related immune senescence or chronic diseases/infections such as diabetes and AIDS/HIV. In 2017, EBVMCU was recognized by WHO and included in the classification of tumors. Mucocutaneous ulcerations often present as indolent, sharply demarcated ulcerations of the gingiva. Over 70 % of these ulcerations occur in the oral and pharyngeal cavities. EBV is secreted in saliva and can develop EBVMCU in association with trauma, such as tooth extraction. We present three patient cases with EBVMCU. We describe the clinical presentation, differential diagnosis and diagnosis, treatment, and clinical outcome.

Original language	English
Article number	100111
Number of pages	6
Journal	Oral Oncology Reports
Volume	8
DOIs	https://doi.org/10.1016/j.oor.2023.100111
Publication status	Published - 1 Dec 2023

Keywords

EBV
Immune system
Mucocutaneous ulceration
Treatment

Access to Document

10.1016/j.oor.2023.100111Licence: CC BY

Cite this

Bittermann, G. K. P., Koper, D. C., Vaassen, L. A. A., van den Hout, M. F. C. M., & Kessler, P. A. W. H. (2023). Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva: A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features. Oral Oncology Reports, 8, Article 100111. https://doi.org/10.1016/j.oor.2023.100111

@article{f39595fc1ea44454916079bfafb48653,

title = "Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva: A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features",

abstract = "Oral ulcerations of the gingiva or mucosa require differential diagnosis. One of these diagnoses may be Epstein-Barr virus (EBV)-positive mucocutaneous ulcer. Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a rare diagnosis and was first described in 2010. It is described as an Epstein-Barr virus (EBV)-mediated B-cell proliferation and occurs in patients with immunosuppression, e.g., therapy with azathioprine, methotrexate, or cyclosporine, but also in patients with age-related immune senescence or chronic diseases/infections such as diabetes and AIDS/HIV. In 2017, EBVMCU was recognized by WHO and included in the classification of tumors. Mucocutaneous ulcerations often present as indolent, sharply demarcated ulcerations of the gingiva. Over 70 % of these ulcerations occur in the oral and pharyngeal cavities. EBV is secreted in saliva and can develop EBVMCU in association with trauma, such as tooth extraction. We present three patient cases with EBVMCU. We describe the clinical presentation, differential diagnosis and diagnosis, treatment, and clinical outcome.",

keywords = "EBV, Immune system, Mucocutaneous ulceration, Treatment",

author = "Bittermann, {G. K.P.} and Koper, {D. C.} and Vaassen, {L. A.A.} and {van den Hout}, {M. F.C.M.} and Kessler, {P. A.W.H.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = dec,

day = "1",

doi = "10.1016/j.oor.2023.100111",

language = "English",

volume = "8",

journal = "Oral Oncology Reports",

publisher = "Elsevier",

}

Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva: A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features. / Bittermann, G. K.P.; Koper, D. C.; Vaassen, L. A.A. et al.
In: Oral Oncology Reports, Vol. 8, 100111, 01.12.2023.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Epstein-Barr virus-positive mucocutaneous ulcer of the gingiva

T2 - A self-limiting disorder of the immune compromised that can present with aggressive clinico-radiological and histomorphological features

AU - Bittermann, G. K.P.

AU - Koper, D. C.

AU - Vaassen, L. A.A.

AU - van den Hout, M. F.C.M.

AU - Kessler, P. A.W.H.

PY - 2023/12/1

Y1 - 2023/12/1

N2 - Oral ulcerations of the gingiva or mucosa require differential diagnosis. One of these diagnoses may be Epstein-Barr virus (EBV)-positive mucocutaneous ulcer. Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a rare diagnosis and was first described in 2010. It is described as an Epstein-Barr virus (EBV)-mediated B-cell proliferation and occurs in patients with immunosuppression, e.g., therapy with azathioprine, methotrexate, or cyclosporine, but also in patients with age-related immune senescence or chronic diseases/infections such as diabetes and AIDS/HIV. In 2017, EBVMCU was recognized by WHO and included in the classification of tumors. Mucocutaneous ulcerations often present as indolent, sharply demarcated ulcerations of the gingiva. Over 70 % of these ulcerations occur in the oral and pharyngeal cavities. EBV is secreted in saliva and can develop EBVMCU in association with trauma, such as tooth extraction. We present three patient cases with EBVMCU. We describe the clinical presentation, differential diagnosis and diagnosis, treatment, and clinical outcome.

AB - Oral ulcerations of the gingiva or mucosa require differential diagnosis. One of these diagnoses may be Epstein-Barr virus (EBV)-positive mucocutaneous ulcer. Epstein-Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) is a rare diagnosis and was first described in 2010. It is described as an Epstein-Barr virus (EBV)-mediated B-cell proliferation and occurs in patients with immunosuppression, e.g., therapy with azathioprine, methotrexate, or cyclosporine, but also in patients with age-related immune senescence or chronic diseases/infections such as diabetes and AIDS/HIV. In 2017, EBVMCU was recognized by WHO and included in the classification of tumors. Mucocutaneous ulcerations often present as indolent, sharply demarcated ulcerations of the gingiva. Over 70 % of these ulcerations occur in the oral and pharyngeal cavities. EBV is secreted in saliva and can develop EBVMCU in association with trauma, such as tooth extraction. We present three patient cases with EBVMCU. We describe the clinical presentation, differential diagnosis and diagnosis, treatment, and clinical outcome.

KW - EBV

KW - Immune system

KW - Mucocutaneous ulceration

KW - Treatment

U2 - 10.1016/j.oor.2023.100111

DO - 10.1016/j.oor.2023.100111

M3 - Article

VL - 8

JO - Oral Oncology Reports

JF - Oral Oncology Reports

M1 - 100111

ER -